The Effectiveness of Repetitive Paravertebral Block with Ropivacaine and Dexmedetomidine for the Prevention of Postherpetic Neuralgia in Patients with Acute Herpes Zoster

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032329

Enrollment

Unknown

Registered

2020-04-26

Start date

2018-01-01

Completion date

Unknown

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic Neuralgia

Interventions

Rop:Paravertebral Block with Ropivacaine only for 3 times

Dex:Paravertebral Block with Ropivacaine and Dexmedetomidine for 3 times

Eligibility

Sex/Gender

All

Age

50 Years to 96 Years

Inclusion criteria

Inclusion criteria: Aged >=50 years; HZ within 7 days after onset of the rash, rash on trunk and extremities.

Exclusion criteria

Exclusion criteria: Rash on perineumhead and face, history of bradycardia or hypotension, and hard to correctly express the severity of pain.

Design outcomes

Primary

Measure	Time frame
Incidence of Postherpetic Neuralgia;	—

Countries

China

Contacts

Public ContactYang Fan

the Second Affiliated Hospital of Nanchang University

hawkyangfan@qq.com+86 15170076770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026